Processing at the authentic HIV-1 PR recognition site and release of the mature p17 matrix and the p24 capsid protein, as a result of the cleavage of the -SQNY-/-PIVQ- cleavage site.
Synonyms
herv-k pr, herv-k(hml-2) pro, herv-k(hml-2) protease, herv-k protease, more
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
Processing at the authentic HIV-1 PR recognition site and release of the mature p17 matrix and the p24 capsid protein, as a result of the cleavage of the -SQNY-/-PIVQ- cleavage site.
Processing at the authentic HIV-1 PR recognition site and release of the mature p17 matrix and the p24 capsid protein, as a result of the cleavage of the -SQNY-/-PIVQ- cleavage site.
-
-
-
-
Processing at the authentic HIV-1 PR recognition site and release of the mature p17 matrix and the p24 capsid protein, as a result of the cleavage of the -SQNY-/-PIVQ- cleavage site.
the enzyme contains the aspartic protease triad Asp-Thr-Gly in the catalytic site
the results do not exclude the possibility that the HERV-K PR could complement an HIV-1 PR whoses function is impaired due to drugs or drug-resistant mutations, they clearly demomstrate that the HERV-K PR cannot substitute for the function of the wild-type HIV-1 PR
the N-terminal cleavage site for HERV-K capsid protein matches the sequence consistently found at the N-terminus of all retroviral capsid proteins. The other cleavage sites correspond well to the simplified version of a cleavage site as an amino acid stretch that is hydrophobic and both accessible and flexible, i.e. apparently the space between separately folded domainsof Gag
identification of human cellular proteins that are substrates of HERV-K(HML-2) Pro employing a modified Terminal Amine Isotopic Labeling of Substrates (TAILS) procedure. Confirmation of cleavage of a majority of selected human proteins in vitro and in co-expression experiments in vivo, overview
the results do not exclude the possibility that the HERV-K PR could complement an HIV-1 PR whoses function is impaired due to drugs or drug-resistant mutations, they clearly demomstrate that the HERV-K PR cannot substitute for the function of the wild-type HIV-1 PR
hundreds of cellular proteins are potential substrates of enzyme HERV-K(HML-2) Pro. Thus, even low-level expression of HERV-K(HML-2) Pro affects levels of a diverse array of proteins and has a functional impact on cell biology and possible relevance for human diseases
2 * 17500, the enzyme is synthesized as monomeric part of the Gag polyprotein or the Gag-Pol polyprotein and autolytically processed to the mature protein dimer, structure overview
2 * 17500, the enzyme is synthesized as monomeric part of the Gag polyprotein or the Gag-Pol polyprotein and autolytically processed to the mature protein dimer, structure overview
the enzyme is synthesized as monomeric part of the Gag polyprotein or the Gag-Pol polyprotein and autolytically processed to the mature protein dimer, autoprocessing at the N-terminal sequence Lys-Ala-Ala-Tyr-Trp-Ala-Ser-Gln
a C-terminally truncated mutant enzyme shows increased affinity for the peptide substrates and increased sensitivity to peptidomimetic inhibitors compared to the wild-type enzyme
two different, enzymatically inactive mutants of HML-2 Pro harboring mutations in catalytic motifs cannot be purified due to inefficient binding to pepstatin A affinity resin
recombinant wild-type and C-terminally truncated mutant enzymes from Escherichia coli by ammonium sulfate fractionation, cation and anion exchange chromatography, and hydrophobic interaction chromatography, or recombinant C-terminally truncated mutant enzyme from inclusion bodies by dialysis and pepstatin A affinity chromatography followed by autoprocession to active, soluble enzme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
213 amino acids of the 3'-end of the HERV-K protease open reading frame are expressed in Escherichia coli. Autocatalytic cleavage of the expressed polypeptide results in a catalytically active 18200 Da protein
cloning of HML-2 Pro including self-processing sites and in-frame flanking sequence, HML-2 Pro is prokaryotically expressed. HML-2 Pro self-processes from the precursor during the expression, purification, and renaturation steps. Coexpression of the enzyme with HA-tagged potential human substrate proteins HSPA90AA1, MAP2K2, and C15orf57 in HEK-293 cells. The HEK293T cells harvested after 5 h do not show evidence of processing of candidate proteins due to apoptotic processes
nucleotide sequence determination and analysis, detailed phylogenetic analysis of virus from primates and humans, and structural analysis of 100 HERV-K(HML-5) provirus sequences, reconstruction of a coding-competent HML-5 provirus, overview
targeting of the HERV-K PR to protease-deficient HIV-1 virions by expressing it as a Vpr fusion partner. The Vpr fusion proteins are sucessfully delivered to the HIV-1 virions, where the HERV-K PR not only autoprocesses itself to ist mature form, but also cleaves a number of HIV-1 polyproteins
the HERV-K113 sequence is cloned into a small plasmid vector. It is shown that based on a substantial LTR-promoter activity, full length messenger RNA and spliced env-, rec- and 1.5 kb (hel)-transcripts are produced. Envelope protein of HERV-K113 is synthesized as an 85 kDa precursor that is found partially processed. The accessory Rec protein is highly expressed and accumulates in the nucleus. Expression analysis reveals synthesis of the Gag precursor and the protease in lysates of transfected HEK-293T cells. The cloned HERV-K113 provirus is not replication competent
in the present study HIV-1 and HCV-1-positive plasma samples are screened for the presence of HERV-K(HML-2) RNA in an RT-PCR using HERV-K pol specific primers. Type 1 and type 2 HERV-K(HML- 2) viral RNA genomes are found to coexist in the same plasma of HIV-1 patients suggesting that HERV-K(HML-2) viral particles are induced in HIV-1-infected individuals